

# INVESTOR PRESENTATION



~ INNOVATING TODAY FOR A HEALTHIER TOMORROW

# AGENDA

AGENDA	PAGE NO.
<u>OUR JOURNEY</u>	3
<u>FOUNDATIONS</u>	4
<u>MISSION , VISION AND STRATEGY</u>	5-6
<u>CLIENTS</u>	7
<u>GEOGRAPHICAL PRESENCE</u>	8-9
<u>KEY PRODUCTS</u>	10
<u>PRODUCTION</u>	11-13
<u>SALES</u>	14-17
<u>FINANCIALS</u>	18-24
<u>SYSCHEM AT A GLANCE</u>	25
<u>LEADERSHIP</u>	26
<u>ESG COMMITMENT</u>	27
<u>SAFE HARBOUR STATEMENT</u>	28
<u>CSR</u>	30
<u>CONTACT US</u>	31



# OUR JOURNEY

**1993**

Syschem India Limited was incorporated on 31 December 1993.

**1996–1998**

The company entered commercial production of Monocrotophos in 1998

Marked the company's entry into mainstream agrochemical manufacturing.

**2001**

Introduced new chemical products such as Deta, DETC, and Ethion.

Strategic shift from single-product dependency to broader chemical portfolio.

**2011–12**

Started commercial production of 7-ACCA, a key drug intermediate for the cephalosporin family of bulk drugs.

This was the company's first major move from agrochemicals into the pharmaceutical sector.

**2017–2018**

The company transitioned its core focus from 7-ACCA toward Antibiotics range.

**2020–Present**

Strengthening manufacturing infrastructure in kalka district Panchkula, Haryana.

Increasing emphasis on

- APIs for domestic + export markets
- API-grade compliance & quality systems

## Operational Infrastructure & Scalability

## Market Reach & Geographic Expansion

## Leadership Capability & Strategic Direction

## Financial Strength & Sustainability



- INSTALLED CAPACITY OF ~ 4200 TPA
- 6 ACRES LAND BANK AREA
- PURSUING ENHANCEMENT AND EXPANSION OF CURRENT FACILITY WITH AN AIM OF 8000 TPA.

- 100+ CONSUMERS AND TRADERS GLOBALLY
- 7+ API SKUs
- Global footprint: 3 Continents. and 10+ Countries

SIL is led by an experienced management team with proficiency of over 3 decades and supports the business in identifying and seizing growth opportunities that will likely arise as a result of changes in demand of APIs.

- REVENUE GROWTH OF 65% IN COMPARISON TO LAST FINANCIAL YEAR
- EBITDA growth of 300% IN COMAPRISON TO LAST FINANCIAL YEAR.
- PAT growth of APROXX 858% IN COMAPRISON TO LAST FINANCIAL YEAR.





The company aims to become one of India's leading manufacturers of APIs and pharmaceutical intermediates by creating long-term value for all stakeholders through innovation, operational excellence, and responsible manufacturing. It is committed to fostering a culture of collaboration, growth, and safety at every level while continuously investing in R&D and quality systems to meet evolving customer and regulatory requirements. The organization also strives to adopt sustainable practices and minimize its environmental impact across the entire value chain.



To become a leading and trusted global partner in the API industry by providing high-quality, innovative, and sustainable solutions. Syschem India Limited is committed to scientific excellence, regulatory compliance, and creating long-term value for customers, employees, and society through ethical and environmentally responsible practices.





## RELIABLE SUPPLY



Syschem India Limited operates a resilient and scalable supply chain backed by integrated manufacturing, disciplined capacity planning, and strong vendor partnerships. This enables the company to deliver critical APIs consistently across domestic and global markets, ensuring reliability even in volatile industry conditions.

## WORLD CLASS QUALITY



Quality excellence is embedded in Syschem's operating DNA. With internationally aligned manufacturing standards, advanced analytical laboratories, and rigorous compliance systems, the company delivers APIs that meet the strictest global regulatory and customer requirements.

## CONTINUOUS INNOVATION



Syschem drives sustainable growth through continuous investments in R&D, process engineering, and product development. By enhancing process efficiency, expanding its product portfolio, and adopting advanced technologies, the company stays ahead of market trends and customer expectations.





# CLIENTS



Medico Remedies Ltd

**Aura Pharmaceuticals Pvt. Ltd**



**LABORATE**  
PHARMACEUTICALS INDIA LTD

**MILÂN**

MILÂN LABORATORIES (INDIA) PVT. LTD.



**CORAL LABORATORIES LTD**  
"We Work For Better Tomorrow!!!"



**LEBEN**  
LABORATORIES PVT. LTD.



**RISHABH**  
LIFESCIENCE PVT. LTD.



**FARMACHEM**  
Life Pvt. Ltd.

**MAXHEAL**  
For Maximum Healing

**MECURE**  
INDUSTRIES  
PLC



**Scott Edil**  
Complementing life



**FINECURE**  
PHARMACEUTICALS LTD.




S.R. Drug Laboratories Pvt. Ltd.


**THEON**  
PHARMACEUTICALS LTD



## SUPPLY ZONE





Expanding operations and improving customer satisfaction are core goals for any thriving business. As we continue to grow, our focus remains on understanding and anticipating the needs of our customers, ensuring that we deliver unparalleled service and quality. This expansion involves not just increasing our geographical footprint, but also enhancing our product offerings and service channels to be more accessible and innovative.





# DOMESTIC PRESENCE

**SUPPLY ZONE**



The Company has a diverse range of APIs in the pharmaceuticals industry that are created chemically. The company has established a foothold in India and the international market.

Syschem's expansive supply chain network is a testament to its commitment to excellence and reliability. Operating across 12 Indian states and reaching over seven international locations, Syschem has established itself as a formidable player in the global market. This extensive reach ensures that the company can efficiently meet the diverse needs of its customers, maintaining a seamless flow of high-quality products.

# KEY PRODUCTS

Amoxicillin T/H

Ampicillin T/H

Flucloxacillin Sod.

Cloxacillin Sod.

Cephalexin

Cephadroxil



Amoxicillin is a widely used antibiotic belonging to the penicillin group of antibiotics.



Ampicillin is a type of antibiotic that is commonly used to treat bacterial infections.



Flucloxacillin is a type of antibiotic that is commonly used to treat bacterial infections



Cloxacillin is a type of antibiotic that is commonly used to treat bacterial infections.



Cephalexin is a type of antibiotic that is commonly used to treat bacterial infections.



Cephadroxil is a type of antibiotic that belongs to the cephalosporin family. It works by inhibiting the growth of bacteria and preventing them from reproducing.






**"Our aim is to increase  
Production on a Year on  
Year basis to achieve  
our target."**

# PRODUCTION VOLUME CURRENT YEAR



**Quarter 1**



**Quarter 2**



**Quarter 3**

**F Y 2 5 - 2 6**




# PRODUCTION VOLUME

**FY24-25**

In Metric T.


Amoxicillin Ampicillin Cephadroxil Cephalosporins



**FY25-26**

Amoxicillin Ampicillin Cephadroxil Flucloxa

In Metric T.








**"Pharmaceutical API Sales involve promoting and supplying high-quality APIs to formulation manufacturers and healthcare partners, supporting the development of safe and effective medicines while driving sustainable revenue growth"**

**RELIABLE SUPPLY**

## FY24-25

Figures in Rs.Lakhs



## FY25-26 (9M)

Figures in Rs.Lakhs



Syschem India Limited delivered strong growth in the first nine months of FY 2025–26, with sales rising from **₹24,748** lakhs in 9M FY 2024–25 to **₹40,631** lakhs in 9M FY 2025–26, representing a robust **65% year-on-year increase**. This sharp expansion across the first three quarters highlights accelerating demand and the company's improving market traction.




# DOMESTIC AND EXPORT SALES VOLUME

## FY 2024-25 V/S FY 2025-26 (9M)

(Figures without GST and Excise)

Figures in Rs.Lakhs


**FY25-26 (9M)**



**2025**

Export SALES :- **10762 Lacs**  
Domestic SALES :- **24783 Lacs**

**FY24-25**



**2024**

Export SALES :- **9089 Lacs**  
Domestic SALES :- **24125 Lacs**


Syschem India Limited delivered strong performance in FY 2025–26 (9M), with export sales of ₹107.62 crore exceeding the full-year FY 2024–25 exports of ₹90.890 crore. Domestic sales also rose to ₹247.83 crore in 9M FY 2025–26 compared to ₹241.25 crore in FY 2024–25, demonstrating robust demand and strong execution across both markets.

# DOMESTIC SALES VOLUME V/S EXPORTS SALES VOLUME

(Figures without GST and Excise)

Figures in Rs.Lakhs


## Q3 DOMESTIC



2025

FY 2024-25 :- **5184 Lacs**  
FY 2025-26 :- **8797 Lacs**

## Q3 EXPORT



2024

FY 2024-25 :- **2616 Lacs**  
FY 2025-26 :- **5399 Lacs**

Syschem India Limited delivered robust year-on-year growth in Q3 FY 2025–26 compared to Q3 FY 2024–25. Export sales surged from ₹26.16 crores to ₹53.99 crores, registering a strong 106% increase, while domestic sales rose from ₹51.84 crores to ₹87.97 crores, reflecting a healthy ~70% growth. This sharp uptick highlights strengthened market demand and improved execution across both segments.



# FINANCIALS

Figures in Rs.Lakhs

2024

**FY24-25 (9M)**

SALES :- ₹24748 Lacs

2025

**FY25-26 (9M)**

SALES :- ₹40631 Lacs

50000

40000

30000

20000

10000

0




FY24-25

FY25-26


# FINANCIALS

Figures in Rs.Lakhs




## FY 24-25

- Q1  
PAT :- **13.67**
- Q2  
PAT :- **-64.01**
- Q3  
PAT :- **50.31**



## FY 25-26

- Q1  
PAT :- **167.35**
- Q2  
PAT :- **189.84**
- Q3  
PAT :- **417.08**




- FY 24-25 (9M)  
PAT :- **-0.03**
- FY 25-26 (9M)  
PAT :- **774.37**




# FINANCIALS

Figures in Rs.Lakhs




FY 24-25

- Q1 EBITDA : 81.86
- Q2 EBITDA :- 6.88
- Q3 EBITDA :-122.1



FY 25-26

- Q1 EBITDA :- 246.93
- Q2 EBITDA :- 331.36
- Q3 EBITDA :- 596.32



FY 24-25

- EBITDA :- 210.84
- EBITDA MARGIN% : 0.85%

FY 25-26

- EBITDA :- 1174.61
- EBITDA MARGIN% : 2.8%

# KEY INCOME STATEMENT HIGHLIGHTS

## Q3 FY24 V/S Q3 FY25

Figures in Rs.Lakhs

Particulars	Q3 FY24	Q3 FY25	YoY% increase	Q2 FY25
Volume				
Revenue from operations	9112.6	16164	<b>177%</b>	11792
EBITDA	122.05	<b>596.32</b>	<b>488%</b>	<b>331.36</b>
EBITDA Margin %	1%	<b>3.7%</b>	<b>3.7%</b>	<b>2.8%</b>
Other income	1.62	<b>0.161</b>		<b>1.05</b>
Depreciation & Amortization	67.95	<b>82.44</b>		<b>75.67</b>
Finance Cost	3.79	17.35		0.97
PBT before exceptional items	50.31	<b>496.52</b>		<b>254.72</b>
Exceptional Items	0	0		0
PBT	<b>50.31</b>	<b>496.52</b>	<b>986%</b>	<b>254.72</b>
Tax Expense	0	<b>79.44</b>		<b>64.88</b>
PAT	<b>50.31</b>	417.08	<b>829%</b>	189.84
PAT Margin %	<b>0.6%</b>	<b>2.6%</b>	<b>4.33%</b>	<b>1.6%</b>
Diluted EPS	<b>0.13</b>	<b>0.96/0.74</b>		<b>0.44/0.34</b>

### Financial Performance Comparison:

Q3 FY 2025-26 marks a defining quarter for Syschem India Limited, with exceptional growth across all key financial metrics. Strong demand, improved capacity utilization, and disciplined cost management drove a **177%** increase in revenue, while operating leverage translated this into a **488%** rise in EBITDA and a **986%** growth in PBT. This performance reflects the strength of our strategy, the resilience of our business model, and our ability to convert growth into sustainable profitability.



# KEY INCOME STATEMENT HIGHLIGHTS

Figures in Rs.Lakhs

## 9M FY24 V/S 9M FY25

Particulars	9M FY 24	9M FY25	YoY%
Volume			
Revenue from operations	24749	40632	164%
EBITDA	375.98	1174.6	312%
EBITDA Margin %	1%	2.8%	2.8%
Other income	2.55	1.732	
Depreciation & Amortization	203.73	233.78	
Finance Cost	7.09	22.23	
PBT before exceptional items	-0.03	918.59	
Exceptional Items	0	0	
PBT	-0.03	918.59	918%
Tax Expense	0	144.32	
PAT	-0.03	857.43	858%
PAT Margin %	-0.16%	1.84%	12.5%
Diluted EPS	0.130	1.78/1.37	



## Revenue Expansion


Company recorded a strong 164% increase in revenue in 9M FY 2025–26 compared to 9M FY 2024–25, reflecting rapid scale-up in operations, stronger customer demand, and expanded market reach across domestic and export segments.



## PBT Surge

PBT grew by an exceptional 918%, highlighting sharp improvement in operating leverage, cost control, and financial discipline, which significantly strengthened the company's earnings quality.

01



02



## EBITDA Growth

EBITDA surged by 312%, driven by higher volumes, improved product mix, and enhanced operating efficiencies, demonstrating Syschem's ability to convert revenue growth into superior operating profitability.



## Profits Trending Up

PAT increased by an outstanding 858%, in comparison to last financial year reflecting strong margin expansion and efficient capital utilization, positioning Syschem for sustained profitability going forward.

04

03



# CAPITAL MARKET INFORMATION

## Shareholding Pattern as on 31st December, 2025

Particulars	% Shareholding
Promoter and Promoter Group	56.71%
Public	43.29%
TOTAL	100%

## Market Indicators

Incorporated	1991
Listed on	BSE
BSE Scrip Code   NSE Symbol	531173   SYSCHEM
Issued Shares	4,35,13,000
Share price (as at 1st February, 2026)	48.59
Market Capital (Rs. Lakhs)	4351.13 lakhs
52 Weeks High/Low	62/35.33



To view our plant kindly visit our website :- [www.syschem.in](http://www.syschem.in)



# LEADERSHIP

## **RANJAN JAIN**

*MANAGING DIRECTOR*

With over 25+ years of entrepreneurial experience. Mr. Jain has led Syschem's strategic diversification and growth in the pharmaceutical and chemical domain.

## **SUNINDER VEER SINGH**

*WHOLE-TIME DIRECTOR*

He oversees Sales and Marketing, bringing over two decades of extensive experience across both national and international markets, and plays a key role in driving the company's commercial strategy and growth.


## **SANJEEV AGRAWAL**

*CHIEF FINANCIAL OFFICER*

With around 30 years of experience in finance, operations, and business development, he plays a key role in Strategic financial decision-making Optimizing capital structure.

**~ INNOVATING TODAY FOR A HEALTHIER TOMORROW**

# ESG COMMITMENT AT SYSCHEM INDIA LTD






# SAFE HARBOUR STATEMENT

This Information Memorandum has been prepared by the Company based on information and data which the Company considers reliable. However, the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, reliability, or fairness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of or any omission from this Presentation is expressly excluded. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Presentation or in relation to the bases and assumptions underlying such projections. You must satisfy yourself in relation to the reasonableness, achievability, and accuracy thereof.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict.





These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the wind power industry in India and worldwide, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences, and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance, or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company, and the Company is not responsible for such third-party statements and projections.


No responsibility or liability is accepted for any loss or damage, howsoever arising, that you may suffer as a result of this Presentation. All responsibility and liability are expressly disclaimed by the Management, the Shareholders, and the Company or any of them or any of their respective directors, officers, affiliates, employees, advisers, or agents.





Syschem respects the cultural diversity and traditions of the communities in which we operate. We partner with indigenous people to build mutual respect, cooperation, and economic inclusion.

Syschem supports poor women in the local community near industrial sites through livelihood and skill development projects. Second, the company's CSR wing encourages employees to be aware of and understand how to care for their own and others' health at work





~ INNOVATING TODAY FOR A HEALTHIER TOMORROW

---

---

# THANK YOU

---

---

For further information contact

[www.syschem.in](http://www.syschem.in)

**Head Office** : 825, FF, NAC Manimajra ,  
Chandigarh-161001

**Factory at** : Village Bargodam, Tehsil Kalka,  
Dist. Panchkula, Haryana-133302



**0172-5070471**



**info@syschem.in**